Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Pfizer’s top-selling breast cancer drug Ibrance also on list Drugmakers plan to ask Trump administration to pause talks The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than ...